Approved TREDAPTIVETM in the European Union: New Lipid modifying therapy to LDL-C.

Patients were started on either 1 g/20 mg of TREDAPTIVE, 1 g of modified-release nicotinic acid or placebo. After four weeks, patients were up to 2 g/40 mg of TREDAPTIVE or 2 g of modified-release nicotinic acid advanced.. Approved TREDAPTIVETM in the European Union: New Lipid – modifying therapy to LDL-C, HDL-C and triglycerides Treatflushing TREDAPTIVE significantly less than modified-release nicotinic acidIn clinical trials, patients the TREDAPTIVE experienced significantly fewermoderate-to – extreme flushing than with modified-release nicotinic acid.

About Merck Sharp & DohmeMerck & Co. (Whitehouse Station, many countries as Merck many countries as Merck Sharp & Dohme or MSD, is a global research-driven pharmaceutical company dedicated to patient comes first founded in 1891., the company is currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts the many uncertainties through far-reaching programs that medicines drugs who need them also to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Forward-Looking Statement..Spanish involved in a low share of cardiac patient into this type of program, such as compared with of the rest of Europe.. Patient heart Rehabilitation Programmeshas carried out Studies at the University Granada, the efficiency a heart Rehabilitation Programme patients with heart diseases should demonstrated. The authors of the trial confirm that it is important to that the heart is to be set rehabilitation of cardiac patients.

Related Posts

Other Posts From Category "healthcare":